Compare ZDGE & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | RLYB |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 24.1M |
| IPO Year | N/A | 2021 |
| Metric | ZDGE | RLYB |
|---|---|---|
| Price | $3.27 | $0.69 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 194.2K |
| Earning Date | 12-12-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,814,000.00 | $674,000.00 |
| Revenue This Year | $3.27 | $17.61 |
| Revenue Next Year | $5.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.71 |
| 52 Week Low | $1.73 | $0.22 |
| 52 Week High | $4.89 | $1.08 |
| Indicator | ZDGE | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 57.24 | 47.14 |
| Support Level | $3.10 | $0.64 |
| Resistance Level | $3.64 | $0.80 |
| Average True Range (ATR) | 0.42 | 0.05 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 39.28 | 29.11 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.